Cogent Biosciences, Inc. (COGT)
| Market Cap | 5.86B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -328.94M |
| Shares Out | 161.05M |
| EPS (ttm) | -2.55 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,307,814 |
| Open | 36.58 |
| Previous Close | 36.61 |
| Day's Range | 36.18 - 37.38 |
| 52-Week Range | 4.55 - 43.73 |
| Beta | 0.47 |
| Analysts | Strong Buy |
| Price Target | 36.21 (-0.41%) |
| Earnings Date | May 6, 2026 |
About COGT
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company also develops CGT4859, a rev... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for COGT stock is "Strong Buy." The 12-month stock price target is $36.21, which is a decrease of -0.41% from the latest price.
News
Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
– Updated presentation on Cogent's potent pan-KRAS(ON) inhibitor, CGT1263, showcasing its selectivity profile which could lead to reduction in skin toxicity associated with multi-RAS inhibitors
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
WALTHAM, Mass. and BOULDER, Colo., April 01, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Transcript: Leerink Global Healthcare Conference 2026
Bezuclastinib is positioned for commercial launch in three indications following positive pivotal trials, with strong differentiation from competitors and significant market opportunities in rare diseases. Commercial infrastructure is advancing, and the pipeline is being refined to focus on the most promising assets.
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Feb. 28, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
SUMMIT NDA for bezuclastinib in patients with NonAdvSM submitted in December 2025; APEX NDA submission for bezuclastinib in patients with AdvSM on track for 1H 2026 PEAK NDA initiated for bezuclastini...
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
WALTHAM, Mass. and BOULDER, Colo., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
- Cogent will submit the PEAK New Drug Application (NDA) under previously announced RTOR designation; on track to complete NDA submission in April 2026 WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences to Initiate New Drug Application (NDA) Submission for Bezuclastinib Under Real-Time Oncology Review (RTOR)
- PEAK trial first ever study to demonstrate statistical significance over an active comparator in GIST patients, with bezuclastinib plus sunitinib combination demonstrating mPFS of 16.5 months and O...
Cogent Biosciences Transcript: 44th Annual J.P. Morgan Healthcare Conference
Bezuclastinib’s three pivotal trials in GIST and systemic mastocytosis showed strong efficacy, with all NDAs set for submission in early 2026 and a U.S. launch planned for later that year. The company is well-funded, expanding its pipeline, and preparing for global commercialization, with ongoing data updates and strategic partnerships under consideration.
Cogent Biosciences Announces Anticipated 2026 Commercial and Clinical Milestones for Bezuclastinib and Precision Therapies Portfolio
WALTHAM, Mass. and BOULDER, Colo., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
Cogent Biosciences Announces Presentation at the 44th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined...
Cogent Biosciences Stock Soared in 2025. Four Executives Sold Shares on the Same Day.
The biotech's chief legal and financial officers were among four executives who sold shares on the same day.
Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in NonAdvanced Systemic Mastocytosis
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences Transcript: Study Result
Bezuclastinib demonstrated rapid, durable, and broad symptom and disease marker improvements in both non-advanced and advanced systemic mastocytosis, with a favorable safety profile and strong correlation between biomarker reduction and symptom relief. NDA submissions are planned soon, with the drug positioned as a potential new standard of care.
Cogent Biosciences Presents Full SUMMIT Results of Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 67th Annual Meeting of the American Society of Hematology (ASH)
-- Bezuclastinib achieves clear clinical benefit across all symptom domains including significant improvements on 11 individual symptoms plus the most severe symptom at baseline -- -- Bezuclastinib de...
Cogent Biosciences Transcript: Jefferies London Healthcare Conference 2025
PEAK phase III data showed bezuclastinib plus sunitinib doubled progression-free survival and achieved a 46% response rate in second-line GIST, with a favorable safety profile and minimal competition. NDA submission is planned for early 2026, targeting a $4B market.
Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference
WALTHAM, Mass. and BOULDER, Colo., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
Cogent Biosciences Announces Pricing of Concurrent Public Offerings of Common Stock and 1.625% Convertible Senior Notes Due 2031
WALTHAM, Mass. and BOULDER, Colo., Nov. 11, 2025 (GLOBE NEWSWIRE) -- Cogent Biosciences, Inc. (“Cogent”) (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetical...
Cogent Biosciences Announces Proposed Concurrent Public Offerings of Convertible Senior Notes Due 2031 and Common Stock
WALTHAM, Mass. and BOULDER, Colo.
Cogent Biosciences' Lead Cancer Drug Cuts Disease Progression Or Death Risk By 50% In Stomach Cancer Trial
Cogent Biosciences, Inc. (NASDAQ:COGT) stock is trading higher on Monday, with a session volume of 10.95 million compared to the average volume of 1.97 million as per data from Benzinga Pro.
Cogent Biosciences Transcript: Study Result
The PEAK Phase III trial showed that bezuclastinib plus sunitinib significantly improved progression-free survival and response rates in imatinib-resistant GIST, with a manageable safety profile and broad efficacy across KIT mutations. Regulatory submission is planned for 2026.
Cogent Biosciences Reports Positive Results from Bezuclastinib PEAK Phase 3 Trial in Gastrointestinal Stromal Tumors (GIST)
16.5 months median progression free survival (mPFS) for bezuclastinib plus sunitinib compared to 9.2 months mPFS for sunitinib monotherapy (HR=0.50, CI: 0.39-0.65; p